Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C A Presant

Showing results (11-20 of 67) with videos related to

Pageof 7
Sort By:
Advanced Drug Delivery Reviews|March 4, 2000
19F-MRS studies of fluorinated drugs in humansW Wolf, C A Presant, V Waluch
Cancer Research|August 1, 1975
Kinetics of both leukemic and normal cell population reduction following 5-azacytidineC A Presant, T Vietti, F Valeriote
NMR in Biomedicine|December 22, 1998
Non-invasive 19F-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studiesW Wolf, V Waluch, C A Presant
Cancer Treatment Reports|June 1, 1984
Mitoxantrone in malignant melanomaC A Presant, R Gams, A Bartolucci
European Journal of Cancer & Clinical Oncology|June 1, 1987
Reversal of cancer chemotherapeutic resistance by amphotericin B--A broad phase I-II pilot studyC A Presant, P Multhauf, G Metter
Annals of Internal Medicine|January 1, 1977
Amphotericin B induction of sensitivity to adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) plus cyclophosphamide in human neoplasiaC A Presant, C Klahr, R Santala
Cancer|September 1, 1977
Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC 409962) and cyclophosphamide therapy of drug-resistant metastatic breast carcinomaC A Presant, A Van Amburg, C Klahr
Cancer|January 15, 1984
Effects of amphotericin B on combination chemotherapy of metastatic sarcomasC A Presant, A A Bartolucci, S Lowenbraun
Cancer|November 1, 1976
Amphotericin B plus 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC no. 409962) in advanced cancer. Phase I and preliminary phase II resultsC A Presant, C Klahr, J Olander, et al.
Cancer|November 1, 1979
Adriamycin, BCNU plus cyclophosphamide (ABC) in advanced carcinoma of the head and neckC A Presant, G Ratkin, C Klahr, et al.
Pageof 7

Showing results (11-20 of 67) with videos related to

Sort By:
Pageof 7
Advanced Drug Delivery Reviews|March 4, 2000
19F-MRS studies of fluorinated drugs in humansW Wolf, C A Presant, V Waluch
Cancer Research|August 1, 1975
Kinetics of both leukemic and normal cell population reduction following 5-azacytidineC A Presant, T Vietti, F Valeriote
NMR in Biomedicine|December 22, 1998
Non-invasive 19F-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studiesW Wolf, V Waluch, C A Presant
Cancer Treatment Reports|June 1, 1984
Mitoxantrone in malignant melanomaC A Presant, R Gams, A Bartolucci
European Journal of Cancer & Clinical Oncology|June 1, 1987
Reversal of cancer chemotherapeutic resistance by amphotericin B--A broad phase I-II pilot studyC A Presant, P Multhauf, G Metter
Annals of Internal Medicine|January 1, 1977
Amphotericin B induction of sensitivity to adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) plus cyclophosphamide in human neoplasiaC A Presant, C Klahr, R Santala
Cancer|September 1, 1977
Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC 409962) and cyclophosphamide therapy of drug-resistant metastatic breast carcinomaC A Presant, A Van Amburg, C Klahr
Cancer|January 15, 1984
Effects of amphotericin B on combination chemotherapy of metastatic sarcomasC A Presant, A A Bartolucci, S Lowenbraun
Cancer|November 1, 1976
Amphotericin B plus 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC no. 409962) in advanced cancer. Phase I and preliminary phase II resultsC A Presant, C Klahr, J Olander, et al.
Cancer|November 1, 1979
Adriamycin, BCNU plus cyclophosphamide (ABC) in advanced carcinoma of the head and neckC A Presant, G Ratkin, C Klahr, et al.
Pageof 7